{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:28:04Z","timestamp":1782448084082,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Cantargia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1038\/s41416-021-01657-7","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T07:02:40Z","timestamp":1639378960000},"page":"1010-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours"],"prefix":"10.1038","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-9991","authenticated-orcid":false,"given":"Debbie","family":"Robbrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Jungels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-1250","authenticated-orcid":false,"given":"Morten Mau","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iben","family":"Spanggaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe \u00d8","family":"Fretland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6471-2072","authenticated-orcid":false,"given":"Tormod Kyrre","family":"Guren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Svedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Thorsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"1657_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/ni.3790","volume":"18","author":"MG Netea","year":"2017","unstructured":"Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, et al. A guiding map for inflammation. Nat Immunol. 2017;18:826\u201331.","journal-title":"Nat Immunol"},{"key":"1657_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.lungcan.2018.06.015","volume":"122","author":"L Millares","year":"2018","unstructured":"Millares L, Barreiro E, Cortes R, Martinez-Romero A, Balcells C, Cascante M, et al. Grupo Colaborativo en C\u00e1ncer de Pulm\u00f3n CIBERES- CIBERONC- SEPAR\u2014Plataforma Biobanco Pulmonar. Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: local patterns and prognostic significance. Lung Cancer. 2018;122:124\u201330.","journal-title":"Lung Cancer"},{"key":"1657_CR3","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1158\/0008-5472.CAN-14-0960","volume":"74","author":"L Wang","year":"2014","unstructured":"Wang L, Zhang LF, Wu J, Xu SJ, Xu YY, Li D, et al. IL-1\u00df-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. Cancer Res. 2014;74:4720\u201330.","journal-title":"Cancer Res"},{"key":"1657_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.celrep.2016.05.085","volume":"16","author":"AG McLoed","year":"2016","unstructured":"McLoed AG, Sherrill TP, Cheng DS, Han W, Saxon JA, Gleaves LA, et al. Neutrophil-derived IL-1\u03b2 impairs the efficacy of NF-\u03baB inhibitors against lung cancer. Cell Rep. 2016;16:120\u201332.","journal-title":"Cell Rep"},{"key":"1657_CR5","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","volume":"78","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018;78:5011\u201322.","journal-title":"Cancer Res"},{"key":"1657_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/1541-7786.MCR-17-0221","volume":"16","author":"A Nomura","year":"2018","unstructured":"Nomura A, Gupta VK, Dauer P, Sharma NS, Dudeja V, Merchant N, et al. NF\u03baB-mediated invasiveness in CD133+ pancreatic TICs is regulated by autocrine and paracrine activation of IL1 signaling. Mol Cancer Res. 2018;16:162\u201372.","journal-title":"Mol Cancer Res"},{"key":"1657_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/bjc.2013.174","volume":"108","author":"S Mitsunaga","year":"2013","unstructured":"Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, et al. Serum levels of IL-6 and IL-1\u03b2 can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 2013;108:2063\u201369.","journal-title":"Br J Cancer"},{"key":"1657_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67:320\u201332.","journal-title":"Gut"},{"key":"1657_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-14-3382","volume":"22","author":"Z Zhuang","year":"2016","unstructured":"Zhuang Z, Ju HQ, Aguilar M, Gocho T, Li H, Iida T, et al. IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-\u03baB activation. Clin Cancer Res. 2016;22:1432\u201344.","journal-title":"Clin Cancer Res"},{"key":"1657_CR10","doi-asserted-by":"publisher","first-page":"6965","DOI":"10.1158\/0008-5472.CAN-11-0588","volume":"71","author":"MC Schmid","year":"2011","unstructured":"Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, et al. Combined blockade of integrin-\u03b14\u03b21 plus cytokines SDF-1\u03b1 or IL-1\u03b2 potently inhibits tumor inflammation and growth. Cancer Res. 2011;71:6965\u201375.","journal-title":"Cancer Res"},{"key":"1657_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ccr.2011.12.006","volume":"21","author":"J Ling","year":"2012","unstructured":"Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, et al. KrasG12D-induced IKK2\/\u03b2\/NF-\u03baB activation by IL-1\u03b1 and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:105\u201320.","journal-title":"Cancer Cell"},{"key":"1657_CR12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1158\/1078-0432.CCR-10-1561","volume":"17","author":"AV Maker","year":"2011","unstructured":"Maker AV, Katabi N, Qin LX, Klimstra DS, Schattner M, Brennan MF, et al. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011;17:1502\u201308.","journal-title":"Clin Cancer Res"},{"key":"1657_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1158\/1541-7786.MCR-08-0201","volume":"7","author":"D Melisi","year":"2009","unstructured":"Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, et al. Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res. 2009;7:624\u201333.","journal-title":"Mol Cancer Res"},{"key":"1657_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nm.2999","volume":"19","author":"M Bruchard","year":"2013","unstructured":"Bruchard M, Mignot G, Derang\u00e8re V, Chalmin F, Chevriaux A, V\u00e9gran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19:57\u201364.","journal-title":"Nat Med"},{"key":"1657_CR15","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-17-1366","volume":"78","author":"D Zhang","year":"2018","unstructured":"Zhang D, Li L, Jiang H, Li Q, Wang-Gillam A, Yu J, et al. Tumor-stroma IL1\u03b2-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res. 2018;78:1700\u201312.","journal-title":"Cancer Res"},{"key":"1657_CR16","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833\u201342.","journal-title":"Lancet"},{"key":"1657_CR17","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.4049\/jimmunol.161.10.5614","volume":"161","author":"EB Cullinan","year":"1998","unstructured":"Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, McIntyre KW, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol. 1998;161:5614\u201320.","journal-title":"J Immunol"},{"key":"1657_CR18","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1074\/jbc.270.23.13757","volume":"270","author":"SA Greenfeder","year":"1995","unstructured":"Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem. 1995;270:13757\u201365.","journal-title":"J Biol Chem"},{"key":"1657_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1074-7613(02)00514-9","volume":"18","author":"DE Smith","year":"2003","unstructured":"Smith DE, Hanna R, Della F, Moore, Chen H, Farese H, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003;18:87\u201396.","journal-title":"Immunity"},{"key":"1657_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/1529-0131(199806)41:6<1083::AID-ART15>3.0.CO;2-9","volume":"41","author":"P Jouvenne","year":"1998","unstructured":"Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum. 1998;41:1083\u201389.","journal-title":"Arthritis Rheum"},{"key":"1657_CR21","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M J\u00e4r\u00e5s","year":"2010","unstructured":"J\u00e4r\u00e5s M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010;107:16280\u201385.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1657_CR22","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","volume":"121","author":"M Askmyr","year":"2013","unstructured":"Askmyr M, \u00c5gerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709\u201313.","journal-title":"Blood"},{"key":"1657_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","volume":"129","author":"A Shastri","year":"2017","unstructured":"Shastri A, Will B, Steidl U, Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017;129:1586\u201394.","journal-title":"Blood"},{"key":"1657_CR24","unstructured":"IL1RAP Summary. The Human Protein Atlas. 2020. https:\/\/www.proteinatlas.org\/ENSG00000196083-IL1RAP. accessed 06 Sept 2020."},{"key":"1657_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/leu.2015.135","volume":"30","author":"N Landberg","year":"2016","unstructured":"Landberg N, Hansen N, Askmyr M, \u00c5gerstam H, Lassen C, Rissler M, et al. IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. Leukemia. 2016;30:253\u2013257.","journal-title":"Leukemia"},{"key":"1657_CR26","unstructured":"IL1RAP Pathology Atlas. The Human Protein Atlas. 2020. https:\/\/www.proteinatlas.org\/ENSG00000196083-IL1RAP\/pathology. accessed 12 Nov 2020."},{"key":"1657_CR27","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","volume":"112","author":"H \u00c5gerstam","year":"2015","unstructured":"\u00c5gerstam H, Karlsson C, Hansen N, Sand\u00e9n C, Askmyr M, von Palffy S, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci USA. 2015;112:10786\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1657_CR28","unstructured":"IL1RAP Protein Summary. The Human Protein Atlas. 2020. https:\/\/www.proteinatlas.org\/ENSG00000196083-IL1RAP\/summary\/rna. accessed 06 Sept 2020."},{"key":"1657_CR29","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-17-2761","volume":"78","author":"S Liu","year":"2018","unstructured":"Liu S, Lee JS, Jie C, Park MH, Iwakura Y, Patel Y, et al. HER2 overexpression triggers an IL1\u03b1 proinflammatory circuit to drive tumorigenesis and promote chemotherapy resistance. Cancer Res. 2018;78:2040\u201351.","journal-title":"Cancer Res"},{"key":"1657_CR30","doi-asserted-by":"publisher","first-page":"12994","DOI":"10.1073\/pnas.1705165114","volume":"114","author":"C Voigt","year":"2017","unstructured":"Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, et al. Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. Proc Natl Acad Sci USA. 2017;114:12994\u201312999.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1657_CR31","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41416-021-01303-2","volume":"124","author":"R Winograd","year":"2021","unstructured":"Winograd R, Simeone DM, Bar-Sagi D. A novel target for combination immunotherapy in pancreatic cancer: IL-1\u03b2 mediates immunosuppression in the tumour microenvironment. Br J Cancer. 2021;124:1754\u20131756.","journal-title":"Br J Cancer"},{"key":"1657_CR32","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H \u00c5gerstam","year":"2016","unstructured":"\u00c5gerstam H, Hansen N, von Palffy S, Sand\u00e9n C, Reckzeh K, Karlsson C, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 2016;128:2683\u201393.","journal-title":"Blood"},{"key":"1657_CR33","unstructured":"Liberg, D, Sime, W, Riva, M, Massoumi, R, Forsberg, G, Von Wachenfeldt, K. The CAN04 antibody targets IL1RAP and inhibits tumor growth in a PDX model for NSCLC. 2016. https:\/\/cantargia.com\/assets\/uploads\/Poster-PEGS-Europe-final.pdf."},{"key":"1657_CR34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1538-7445.AM2018-1769","volume":"78","author":"D Liberg","year":"2018","unstructured":"Liberg D, \u00d6nnervik PO, Riva M, Larsson L, Forsberg G, Von Wachenfeldt K. Abstract 1769: Antibody blockade of ILRAP signaling reduces metastasis in a breast cancer model. Cancer Res. 2018;78:1769.","journal-title":"Cancer Res"},{"key":"1657_CR35","unstructured":"Liberg, D. The CAN04 antibody targets IL1RAP and mediates tumor growth inhibition and increased cisplatin sensitivity in a patient-derived xenograft model for non-small cell lung cancer. 2018. https:\/\/cantargia.com\/assets\/uploads\/Cantargia_San-Diego-CAN04-and-chemotherapy.pdf."},{"key":"1657_CR36","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1158\/1538-7445.AM2020-2269","volume":"80","author":"C Rydberg Millrud","year":"2020","unstructured":"Rydberg Millrud C, von Wachenfeldt K, Falk HH, Forsberg G, Liberg D. Abstract 2269: The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy. Cancer Res. 2020;80:2269.","journal-title":"Cancer Res"},{"key":"1657_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1415","volume":"4","author":"J Vakkila","year":"2004","unstructured":"Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641\u201348.","journal-title":"Nat Rev Immunol"},{"key":"1657_CR38","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1038\/sj.onc.1209423","volume":"25","author":"SS M\u00fcerk\u00f6ster","year":"2006","unstructured":"M\u00fcerk\u00f6ster SS, Lust J, Arlt A, H\u00e4sler R, Witt M, Sebens T, et al. Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene. 2006;25:3973\u201381.","journal-title":"Oncogene"},{"key":"1657_CR39","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"1657_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1657_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6:576\u201388.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1657_CR42","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","volume":"126","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739\u201348.","journal-title":"Circulation"},{"key":"1657_CR43","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217\u201324.","journal-title":"Blood"},{"key":"1657_CR44","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207\u201319.","journal-title":"N Engl J Med"},{"key":"1657_CR45","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2146\/ajhp140282","volume":"72","author":"GW Jean","year":"2015","unstructured":"Jean GW, Comeau JM. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. Am J Health Syst Pharm. 2015;72:933\u201342.","journal-title":"Am J Health Syst Pharm"},{"key":"1657_CR46","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","volume":"111","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094\u20131100.","journal-title":"Blood"},{"key":"1657_CR47","doi-asserted-by":"publisher","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","volume":"28","author":"S Rosell\u00f3","year":"2017","unstructured":"Rosell\u00f3 S, Blasco I, Garc\u00eda Fabregat L, Cervantes A, Jordan K. ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;28:iv100\u2013iv118.","journal-title":"Ann Oncol"},{"key":"1657_CR48","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jaci.2008.04.005","volume":"121","author":"WB Cherry","year":"2008","unstructured":"Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121:1484\u201390.","journal-title":"J Allergy Clin Immunol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01657-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01657-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01657-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:13:18Z","timestamp":1676063598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01657-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4,1]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01657-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical study protocol and other relevant study documents were approved by the applicable regional review boards\/ethic committees (not listed because of limited word space). Written informed consent was obtained from all patients prior to any study related procedure. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DR, CJ, MMS, FE, S\u00d8F and TKG report no personal conflict of interest to declare regarding this manuscript. IS reports no personal conflict of interest except for travel expenses and accommodation from Roche. PA reports consulting for Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius and Deloitte; honoraria from Synthon, Amgen, Novartis and Gilead; travel grants from Amgen, MSD, Pfizer and Roche. DL and LT are Cantargia employees. CS is a consultant for Cantargia. NS reports consultation or attending advisory boards for AIMM Therapeutics, Boehringer Ingelheim and Ellipses Pharma; receiving research grants for the institute from AB Science, Abbvie, Actuate Therapeutics, Amgen, Array, AstraZeneca\/MedImmune, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Cantargia, Cytovation, Deciphera, Genentech\/Roche, GlaxoSmithKline, Incyte, InteRNA, Lilly, Merck Sharp & Dohme, Merus, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Taiho and Takeda (outside the submitted work). AA reports advisory role, research grants to the Institute and speaker fees from: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer and Leo Pharma. Erasmus MC Cancer Institute, Rotterdam, was financially supported by Cantargia to perform their part of this clinical trial. Department of Oncology, Rigshospitalet, Copenhagen, collaborates and received research funding from: AstraZeneca, Bristol-Myers Squibb, Loxo\/Lilly, Alligator Bioscience, Cantargia, Incyte, Pfizer, Orion, Roche, MSD, Genentech, Loxa\/Bayer, Symphogen, Puma Biotechnology, Genmab, and Novartis. Institut Jules Bordet\u2014Universit\u00e9 Libre de Bruxelles, Brussels, received research funding from Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}